Abbott Laboratories (ABT) has drawn fresh attention after unveiling Libre Assist, an AI driven feature in its Libre app that ...

The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties.

Buy Abbott: defensive compounder with recurring cash flow. Libre diabetes devices drive growth; 2025 guidance reaffirmed.

A look at Exact Sciences Corporation’s acquisition by Abbott: review EXAS revenue growth, margins, and CRC/MRD screening ...

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson ...

Over the past six months, Abbott Laboratories’s shares (currently trading at $125.45) have posted a disappointing 7.9% loss, ...

Abbott Laboratories must pay $495 million in damages in the case of a girl who developed a serious gastrointestinal disease as a premature infant after consuming Abbott formula, a Missouri jury ...

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. First-quarter sales increased 4 ...

Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device. This ...

Drugmakers Novo Nordisk and Eli Lilly have been making headlines in recent times, thanks to their sought-after weight loss drugs. In fact, the products have become so popular that demand has surpassed ...

Novo Nordisk and Eli Lilly have generated billions of dollars in revenue selling weight loss drugs. Abbott Labs is launching a complementary product for those on the weight loss path. Abbott Labs is ...